1. Home
  2. IPHA vs BKKT Comparison

IPHA vs BKKT Comparison

Compare IPHA & BKKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IPHA
  • BKKT
  • Stock Information
  • Founded
  • IPHA 1999
  • BKKT 2018
  • Country
  • IPHA France
  • BKKT United States
  • Employees
  • IPHA N/A
  • BKKT N/A
  • Industry
  • IPHA Biotechnology: Pharmaceutical Preparations
  • BKKT Computer Software: Prepackaged Software
  • Sector
  • IPHA Health Care
  • BKKT Technology
  • Exchange
  • IPHA Nasdaq
  • BKKT Nasdaq
  • Market Cap
  • IPHA 160.1M
  • BKKT 156.2M
  • IPO Year
  • IPHA 2019
  • BKKT N/A
  • Fundamental
  • Price
  • IPHA $2.05
  • BKKT $9.69
  • Analyst Decision
  • IPHA Strong Buy
  • BKKT Strong Buy
  • Analyst Count
  • IPHA 1
  • BKKT 1
  • Target Price
  • IPHA $11.00
  • BKKT $13.00
  • AVG Volume (30 Days)
  • IPHA 14.6K
  • BKKT 1.0M
  • Earning Date
  • IPHA 09-17-2025
  • BKKT 11-12-2025
  • Dividend Yield
  • IPHA N/A
  • BKKT N/A
  • EPS Growth
  • IPHA N/A
  • BKKT N/A
  • EPS
  • IPHA N/A
  • BKKT N/A
  • Revenue
  • IPHA $14,839,695.00
  • BKKT $3,778,532,000.00
  • Revenue This Year
  • IPHA $350.96
  • BKKT N/A
  • Revenue Next Year
  • IPHA $32.92
  • BKKT N/A
  • P/E Ratio
  • IPHA N/A
  • BKKT N/A
  • Revenue Growth
  • IPHA N/A
  • BKKT 111.83
  • 52 Week Low
  • IPHA $1.29
  • BKKT $6.81
  • 52 Week High
  • IPHA $3.51
  • BKKT $37.21
  • Technical
  • Relative Strength Index (RSI)
  • IPHA 46.87
  • BKKT 48.26
  • Support Level
  • IPHA $1.93
  • BKKT $9.22
  • Resistance Level
  • IPHA $2.19
  • BKKT $10.50
  • Average True Range (ATR)
  • IPHA 0.11
  • BKKT 0.73
  • MACD
  • IPHA -0.01
  • BKKT 0.35
  • Stochastic Oscillator
  • IPHA 49.66
  • BKKT 64.86

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

About BKKT Bakkt Holdings Inc.

Bakkt Holdings Inc operates technology that connects the digital economy by offering a platform for crypto and redeeming loyalty points. Its institutional-grade technology platform provides a custody solution that caters to more experienced market participants to store crypto and provides consumers, businesses, and institutions with the ability to buy, sell, and store crypto in a simple, intuitive digital experience accessed via application programming interfaces (APIs) or embedded web experience and Loyalty offers a full spectrum of content that clients can make available to its customers when redeeming loyalty currencies. It generates revenue in the form of Subscription and service and Transaction revenue.

Share on Social Networks: